HUP0102475A2 - Új acil-pszeudopeptidek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Új acil-pszeudopeptidek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0102475A2
HUP0102475A2 HU0102475A HUP0102475A HUP0102475A2 HU P0102475 A2 HUP0102475 A2 HU P0102475A2 HU 0102475 A HU0102475 A HU 0102475A HU P0102475 A HUP0102475 A HU P0102475A HU P0102475 A2 HUP0102475 A2 HU P0102475A2
Authority
HU
Hungary
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
containing same
neutral
Prior art date
Application number
HU0102475A
Other languages
English (en)
Inventor
Jacques Bauer
Olivier Richard Martin
Original Assignee
Om Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Om Pharma filed Critical Om Pharma
Publication of HUP0102475A2 publication Critical patent/HUP0102475A2/hu
Publication of HUP0102475A3 publication Critical patent/HUP0102475A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/10—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A találmány az (I) általános képletű vegyületekre vonatkozik, ahol aképletben R1 és R2 jelentése egymástól függetlenül adott esetbenszubsztituált 2-24 szénatomos telített vagy telítetlen, egyenes vagyelágazó szénláncú karbonsavból származó acilcsoport; m, p és q értéke1-10; n értéke 0-10; X és Y jelentése hidrogénatom vagy valamelysavcsoport, amely semleges vagy töltött formában állhat, azzal amegszorítással, hogy X és Y közül legalább az egyik jelentésesavcsoport semleges vagy töltött formában, A és B jelentése egymástólfüggetlenül oxigénatom, kénatom vagy -NH- képletű iminocsoport. Atalálmány kiterjed a fenti vegyületek előállítására és ezekettartalmazó gyógyszerkészítményekre. A találmány szerinti vegyületekelsősorban immunomodulátor tulajdonságokkal rendelkeznek. Ó
HU0102475A 1998-06-30 1999-06-23 Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same HUP0102475A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9801396 1998-06-30
PCT/IB1999/001170 WO2000000462A1 (fr) 1998-06-30 1999-06-23 Nouveaux pseudodipeptides acyles, leur mode de preparation et les compositions pharmaceutiques en renfermant

Publications (2)

Publication Number Publication Date
HUP0102475A2 true HUP0102475A2 (hu) 2001-11-28
HUP0102475A3 HUP0102475A3 (en) 2001-12-28

Family

ID=9522667

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102475A HUP0102475A3 (en) 1998-06-30 1999-06-23 Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same

Country Status (21)

Country Link
US (2) US7157092B1 (hu)
EP (1) EP1091928B1 (hu)
JP (1) JP4699609B2 (hu)
KR (1) KR100766016B1 (hu)
CN (1) CN1168702C (hu)
AR (1) AR029877A1 (hu)
AT (1) ATE355266T1 (hu)
AU (1) AU761396B2 (hu)
BR (1) BR9911329A (hu)
CA (1) CA2337807C (hu)
CZ (1) CZ302062B6 (hu)
DE (1) DE69935330T2 (hu)
DK (1) DK1091928T3 (hu)
EE (1) EE04489B1 (hu)
ES (1) ES2284275T3 (hu)
HU (1) HUP0102475A3 (hu)
PL (1) PL195764B1 (hu)
RU (1) RU2223262C2 (hu)
SK (1) SK287073B6 (hu)
TW (1) TWI255808B (hu)
WO (1) WO2000000462A1 (hu)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE355266T1 (de) * 1998-06-30 2006-03-15 Om Pharma Neue acylierte pseudodipeptide, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen
WO2001046127A1 (fr) * 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
DE60234092D1 (de) * 2001-01-30 2009-12-03 Univ Virginia Agonisten und antagonisten von sphingosin-1-phosphatrezeptoren
ES2335979T3 (es) 2001-09-14 2010-04-07 Cytos Biotechnology Ag Empaquetamiento de cpg inmunoestimuladores en particulas similares a virus: metodo de preparacion y su uso.
RU2326693C2 (ru) 2002-07-18 2008-06-20 Цитос Байотекнолоджи Аг Конъюгаты гаптен-носитель и их применение
NZ542323A (en) 2003-03-26 2008-07-31 Cytos Biotechnology Ag Melan-A peptide analogue-virus-like-particle conjugates
WO2005117958A1 (en) 2004-05-28 2005-12-15 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
AR053833A1 (es) 2005-03-23 2007-05-23 Glaxosmithkline Biolog Sa Composicion inmunogenetica
RU2451523C2 (ru) 2005-12-14 2012-05-27 Цитос Биотехнологи Аг Упакованные иммуностимулирующей нуклеиновой кислотой частицы, предназначенные для лечения гиперчувствительности
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP3470080A1 (en) 2005-12-22 2019-04-17 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
KR20080105048A (ko) * 2006-03-09 2008-12-03 옴 파르마 면역조절 화합물 및 염증성 사이토킨의 과생성에 관련된 질병의 치료
US20100021503A1 (en) 2006-03-30 2010-01-28 Glaxosmithkline Biologicals S.A. Immunogenic composition
NZ573622A (en) 2006-06-12 2011-12-22 Cytos Biotechnology Ag Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
KR20140069379A (ko) 2006-07-17 2014-06-09 글락소스미스클라인 바이오로지칼즈 에스.에이. 인플루엔자 백신
MX2009000650A (es) 2006-07-18 2009-07-02 Secretary Of The Army The Unit Vacunas para malaria.
US8323664B2 (en) 2006-07-25 2012-12-04 The Secretary Of State For Defence Live vaccine strains of Francisella
EP2086582B1 (en) 2006-10-12 2012-11-14 GlaxoSmithKline Biologicals s.a. Vaccine comprising an oil in water emulsion adjuvant
EA021391B1 (ru) 2007-03-02 2015-06-30 Глаксосмитклайн Байолоджикалс С.А. Способ индукции иммунного ответа, вакцинная композиция, ее применение и набор
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
CN101784282B (zh) 2007-06-26 2015-07-08 葛兰素史密丝克莱恩生物有限公司 包含肺炎链球菌荚膜多糖缀合物的疫苗
EP2020240A1 (en) * 2007-07-30 2009-02-04 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Methods and substances for the treatment of Alzheimer's
EP3118213A1 (en) 2007-12-19 2017-01-18 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Soluble forms of hendra and nipah virus f glycoprotein and uses thereof
SI2222710T1 (sl) 2007-12-24 2016-11-30 Id Biomedical Corporation Of Quebec Rekombinatni RSV antigeni
CA2720961A1 (en) 2008-04-16 2009-10-22 William Ripley Ballou, Jr. Streptococcus pneumonia vaccine
AU2009323996A1 (en) 2008-12-03 2011-07-07 Institut Pasteur Use of phenol-soluble modulins for vaccine development
WO2010079081A1 (en) 2009-01-07 2010-07-15 Glaxosmithkline Biologicals S.A. Methods for recovering a virus or a viral antigen produced by cell culture
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
US20110293660A1 (en) 2009-02-06 2011-12-01 Bruno Rene Andre Novel method
WO2010094663A1 (en) 2009-02-17 2010-08-26 Glaxosmithkline Biologicals S.A. Inactivated dengue virus vaccine with aluminium-free adjuvant
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
CN102548578A (zh) 2009-06-24 2012-07-04 魁北克益得生物医学公司 疫苗
CN102481359B (zh) 2009-06-24 2015-08-19 葛兰素史密斯克莱生物公司 重组rsv抗原
BR112012001666A2 (pt) 2009-07-15 2019-09-24 Novartis Ag composições de proteína rsv f e métodos para fazer as mesmas
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
ES2538474T3 (es) 2009-09-25 2015-06-22 Glaxosmithkline Biologicals S.A. Ensayo de inmunodifusión para el virus de la gripe
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
WO2011101332A1 (en) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
EP2566958B1 (en) 2010-05-03 2015-12-30 GlaxoSmithKline Biologicals S.A. Method for inactivating influenza virus
GB201009273D0 (en) 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
JP6138047B2 (ja) 2010-10-15 2017-05-31 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サイトメガロウイルスｇＢ抗原
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
SG194733A1 (en) 2011-05-17 2013-12-30 Glaxosmithkline Biolog Sa Vaccine against streptococcus pneumoniae
JP2015514696A (ja) 2012-03-18 2015-05-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ヒト・パピローマウイルスに対するワクチン接種方法
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
CA2879939A1 (en) 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Novel method
UY35418A (es) 2013-03-15 2014-10-31 Glaxosmithkline Biolog Sa Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
EP3024476A1 (en) 2013-07-26 2016-06-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
US20160193322A1 (en) 2013-08-05 2016-07-07 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
US10392603B2 (en) 2013-08-30 2019-08-27 The Chemo-Sero-Therapeutic Research Institute Method of viral purification
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
WO2015130584A2 (en) 2014-02-25 2015-09-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
WO2015165480A1 (en) 2014-04-30 2015-11-05 Institute For Research In Biomedicine Human cytomegalovirus vaccine compositions and method of producing the same
EP3888676A1 (en) 2014-06-13 2021-10-06 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
US20180186897A1 (en) 2015-06-26 2018-07-05 Institute For Research In Biomedicine Novel vaccines in prevention and treatment of malaria
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
US11911553B2 (en) * 2018-07-06 2024-02-27 Fenwal, Inc. Systems and methods for concentrating cells with a syringe and a centrifuge
EP4004018A1 (en) 2019-07-24 2022-06-01 GlaxoSmithKline Biologicals SA Modified human cytomegalovirus proteins
CN112329267B (zh) * 2020-11-26 2022-08-16 中国核动力研究设计院 一种基于特征线法的组合几何中子输运处理方法及装置
MX2023006320A (es) 2020-12-02 2023-06-14 Glaxosmithkline Biologicals Sa Cadena donante complementada fimh.
WO2022162012A2 (en) 2021-01-26 2022-08-04 Eth Zurich Antibodies broadly targeting coronaviruses and uses thereof
WO2022161598A1 (en) 2021-01-26 2022-08-04 Eth Zurich Antibodies broadly targeting coronaviruses and uses thereof
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61227586A (ja) * 1985-03-30 1986-10-09 Dai Ichi Seiyaku Co Ltd ジサツカライド誘導体およびその塩
US4746742A (en) * 1985-11-28 1988-05-24 Toho Yakuhin Kogyo Kabushiki Kaisha Analogs of nonreducing monosaccharide moiety of lipid A
DE4229877C2 (de) * 1992-09-04 1994-09-15 Max Delbrueck Centrum Phospho- bzw. Phosphono-(N-acyl)-serine und ihre Herstellung
EP0668289A4 (en) * 1993-09-07 1998-10-21 Suntory Ltd NEW DISACCHARIDE DERIVATIVE.
PL181241B1 (pl) * 1993-11-17 2001-06-29 Deutsche Om Arzneimittel Gmbh Disacharydy beta(1 6)glukozoaminowe, sposób wytwarzania disacharydu beta(1 6) glukozoaminowego, zawierająca je kompozycja farmaceutyczna i środek immunomodulujący i/lub przeciwnowotworowy oraz szczepionka
ATE355266T1 (de) * 1998-06-30 2006-03-15 Om Pharma Neue acylierte pseudodipeptide, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen

Also Published As

Publication number Publication date
PL195764B1 (pl) 2007-10-31
EE200000791A (et) 2002-02-15
WO2000000462A1 (fr) 2000-01-06
EP1091928A1 (fr) 2001-04-18
HUP0102475A3 (en) 2001-12-28
TWI255808B (en) 2006-06-01
JP4699609B2 (ja) 2011-06-15
CZ302062B6 (cs) 2010-09-22
AU4284899A (en) 2000-01-17
SK287073B6 (sk) 2009-11-05
KR20010083078A (ko) 2001-08-31
PL345040A1 (en) 2001-11-19
DE69935330T2 (de) 2007-10-31
CN1168702C (zh) 2004-09-29
DK1091928T3 (da) 2007-07-23
BR9911329A (pt) 2001-10-16
AU761396B2 (en) 2003-06-05
US20060148678A1 (en) 2006-07-06
JP2002519338A (ja) 2002-07-02
US7157092B1 (en) 2007-01-02
ES2284275T3 (es) 2007-11-01
AR029877A1 (es) 2003-07-23
KR100766016B1 (ko) 2007-10-11
EE04489B1 (et) 2005-06-15
SK18872000A3 (sk) 2001-07-10
CA2337807A1 (fr) 2000-01-06
CZ20004893A3 (en) 2001-05-16
CA2337807C (fr) 2012-08-21
CN1306504A (zh) 2001-08-01
DE69935330D1 (de) 2007-04-12
EP1091928B1 (fr) 2007-02-28
RU2223262C2 (ru) 2004-02-10
ATE355266T1 (de) 2006-03-15

Similar Documents

Publication Publication Date Title
HUP0102475A2 (hu) Új acil-pszeudopeptidek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
DE69231759D1 (de) Verfahren zur Herstellung von Amidderivaten aus Haloaminotriazinen und Säurehalogeniden
HUP9702036A1 (hu) Leukocitaadhéziót gátló és VLA-4-antagonista vegyületek valamint e vegyületeket tartalmazó gyógyászati készítmények
GB1511366A (en) Aliphatic carboxylic acid esters of vitamin e and process for preparation thereof
ES8404184A1 (es) Un procedimiento para la prepracion de nuevos derivados de acidos 2-carbamimidoil-1-,carbadestiapen-2-en-3-carboxilados.
GB2232995A (en) Assays utilizing improved chemiluminescent esters,thioesters,thioesters and amides
ES479168A1 (es) Un procedimiento para la preparacion de derivados de acido 7&-metoxicefalosporanico.
AU1521988A (en) Novel beta-d-phenyl-thioxylosides, their method of preparation and their use as therapeutics
MXPA03000547A (es) Uso de derivados de amidas de acido valproico y de acido 2-valproenico, para el tratamiento de manias en trastornos bipolares.
HUP9701660A2 (hu) 10,13,15-trioxa-triciklo[9.2.1.1. 9.6]pentadekanon-származékok, eljárás ezek előállítására, és az e vegyületeket tartalmazó gyógyászati készítmények
TR200101083T2 (tr) (7alfa,17alfa)-17-hidroksi- 7-metil-19-nor-17-pregn-5 (10)-en-20-in-3-on içeren yüksek saflıkta bileşim.
ATE10735T1 (de) Verfahren zur herstellung von chinonderivaten.
PL336857A1 (en) Heterocyclic compounds, method of obtaining them and pharmaceutic composition containing such compounds
HUP0105307A2 (hu) Acetilénkötést tartalmazó heteroaril-szulfonamid- és foszfinsavamid-hidroxánsav származékok, mint TACE gátlók és ezeket tartalmazó gyógyszerkészítmények és eljárás a vegyületek előállítási eljárására
ES8200689A1 (es) Un procedimiento para la produccion de analogos de cefalosporina.
ES8704081A1 (es) Un procedimiento para la preparacion de nuevas 3-alcoxi-2-(n-pirrolidino)-n-piridil-n-furilmetilpropilaminas
ES8307246A1 (es) "procedimiento de preparacion de nuevos compuestos de lactama".
ES8607289A1 (es) Procedimiento para la preparacion de nuevas 3-alcoxi-2-(n-pirrolidino)-n-pirimidinil-o-n-pirazinil propilaminas.
ATE1143T1 (de) Prostan-derivate, verfahren zu ihrer herstellung und ihre pharmazeutischen zusammensetzungen.
ES8403922A1 (es) "procedimiento para preparar nuevos esteres de acido tiolfosforico"
AP9901566A0 (en) Novel erythromycin derivatives, method of preparation and application as medicines.
ES8403096A1 (es) Procedimiento para preparar derivados fluorados de alcano diamina, inhibidores de decarboxilasa.
YU37198A (sh) Novi derivati 1(2h) hinolin karboksilne kiseline, postupak za njihovo dobijanje i njihova primena za sintezu proizvoda koji imaju antibiotička dejstva
ES8600318A1 (es) Procedimiento para la obtencion de esteres de acido fosfonico
GB1478070A (en) Esters of o-alkyloxycarbonyl and o-alkylthiocarbonyl- naphthohydroxamic acids their preparation and their miticidal compositions comprising them

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished